India to set up 3 bulk drug parks to manufacture APIs
11 January 2021
The Central government will set up three bulk drug parks to manufacture chemical compounds or active pharmaceutical ingredients (APIs) for medicines and reduce their imports from China.
The bulk drug parks will be set up at an investment of Rs 14,300 crore in partnership with states to make chemicals for live-saving drugs.
Though India is the biggest exporter of medicines to the world, China is the main supplier of chemicals (APIs) used in making drugs.
The government also plans to set up four additional parks to manufacture a range of medical devices as an import-substitute under the Union government's Atmanirbhar Bharat programme in the pharma sector.
The Union Cabinet on 20 March 2020 approved the schemes to set up three bulk drug parks to manufacture APIs and intermediates over the next five years.
It also issued guidelines on 27 July 2020 for setting up the parks for making ingredients and medical devices.
Karnataka, Andhra Pradesh, and Himachal Pradesh are among 14 states in the race to set up the parks by offering land, other facilities, and incentives.
The Centre is setting up five urea plants with a capacity of 12 lakh tpa across the country at an estimated cost of Rs 50,000 crore to be self-sufficient in fertilisers for increasing food production. Of these, a urea plant at Ramagundam in Telangana will soon be ready for commencing production.